Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles.

At 24 hours, we observed a highly significant decrease in KRAS expression in those groups treated with KRAS-siRNA NP versus control cells or scramble (SC) siRNA NP treated cells (both p < 0.0001 ), with a reduction in KRAS RNA expression from 55–70% ( Figure 2A ).

also in 132,142 other papers